Who is the CEO of Dong-a ST?

According to the DART company overview, Dong-a ST's representative director is 정재훈 (name as registered in Korean). The company was founded on 2013-03-04.

Where is Dong-a ST listed?

Dong-a ST trades on the Korea Exchange KOSPI market under the ticker 170900. Its fiscal year ends in December.

Does Dong-a ST pay a dividend?

Yes. For fiscal 2025, Dong-a ST paid a cash dividend of ₩700 per common share, a 1.4% yield as stated in its annual report. The prior year's dividend was ₩700.

Does Dong-a ST have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Turnaround (latest quarter swung to an operating profit from a loss a year earlier); Clinical trial filing (filing on clinical trial plans or results (90 days)). These are factual flags, not investment advice.

Which companies are in the same industry as Dong-a ST?

Under the Korean Standard Industrial Classification recorded on DART, Dong-a ST is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.

Dong-a ST KRX:170900KOSPI

동아에스티 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h10

Articles, 7 days42

DART filings, 7 days3

Articles tracked121since Sep 11

In Q2 2026, Dong-a ST reported revenue of ₩225bn, up 15.8% year on year, and operating profit of ₩6.3bn. Dong-a ST (동아에스티) appeared in 42 Korean news articles and 3 DART filings over the past seven days. Coverage peaked on Oct 27 with 25 articles. The most common catalyst was earnings (11). It was most often mentioned alongside ST Pharm, Dong-A Socio Holdings and 글로벌테크놀로지.

Filing signals Turnaround Clinical trial filing Screener

Dong-a ST quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩225bn	+15.8%	₩6.3bn margin 2.8%	₩1.4bn
Q1 2026	₩204bn	+11.8%	₩7.8bn margin 3.8%	₩7.9bn
Q4 2025 derived	₩217bn	+21.4%	−₩2.7bn margin −1.3%	−₩11.9bn
Q3 2025	₩216bn	+12.8%	₩14.0bn margin 6.5%	₩8.5bn
Q2 2025	₩194bn	+12.5%	−₩5.8bn margin −3.0%	−₩21.8bn
Q1 2025	₩182bn	+17.2%	−₩4.8bn margin −2.6%	−₩12.3bn
Q4 2024 derived	₩179bn	-1.3%	−₩7.3bn margin −4.1%	₩12.2bn
Q3 2024	₩192bn	+14.9%	₩4.3bn margin 2.3%	−₩13.9bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Dong-a ST top stories 2 weeks, by number of outlets

1
동아에스티, '이코트로킨라' 외용제 가능성 확인…건선 제형 확장
6 outlets · 6 articlesFirst report Oct 27 09:18 메디파나뉴스
2
동아에스티, 당뇨병 2제 복합제 ‘슈가엠파정’ 국내 품목허가 획득
5 outlets · 5 articlesFirst report Oct 30 16:11 더바이오Regulatory approval
3
동아에스티, 3분기 영업이익 214억원…전년 대비 27.7% 증가
4 outlets · 4 articlesFirst report Oct 27 11:58 더트래커Earnings
4
동아에스티, 3분기 매출 2,065억 원… 2분기 연속 2,000억 돌파
3 outlets · 3 articlesFirst report Oct 27 13:13 디스커버리뉴스
5
동아에스티, 솔티드와 AI 보행분석 솔루션 ‘뉴로게이트’ 국내 독점 판매
2 outlets · 2 articlesFirst report Oct 21 08:32 한국금융신문
6
동아에스티, 3Q 매출 4.1% 증가 2065억원…2분기 연속 2000억원 매출 돌파
2 outlets · 2 articlesFirst report Oct 27 11:51 더바이오Earnings

Latest Dong-a ST news Korean headlines

16:11
Major동아에스티, 당뇨병 2제 복합제 ‘슈가엠파정’ 국내 품목허가 획득
더바이오Regulatory approval
4 more on this story · 4 outlets
- [공시] 동아에스티, 당뇨병 복합제 ‘슈가엠파정’ 국내 품목허가이슈밸리 · 16:22
- 동아에스티, 당뇨 복합제 '슈가엠파정' 국내 품목허가 취득스마트비즈 · 16:53
- 동아에스티, 당뇨병 신약 '슈가엠파정' 국내 품목허가 획득딜사이트 · 17:27
- 동아에스티, 당뇨병 복합제 '슈가엠파' 국내 허가 획득메디파나뉴스 · 19:07
15:24
동아에스티, 산업부 장관 표창…ESG 지속가능경영 성과 인정
메디파나뉴스
1 more on this story · 1 outlets
- 동아에스티, 지속가능경영 성과로 산업부 장관 표창조선비즈 · 16:32
15:23

[위클리오늘] 산업일반 소식_제이브이엠, 동아에스티(10.30)
위클리오늘JVM
13:49

동아에스티, '슈가엠파정' 허가…에보글립틴 복합제 영토 확장
메디팜스투데이
09:46

Major동아에스티 메타비아, 비만치료제 'DA-1726' 글로벌 학회서 임상1상 발표
더구루Clinical trial글로벌테크놀로지
Oct 2907:26

Major동아에스티 기술이전 DA-1726, 美학회서 간지방·체중감소 임상 공개
메디코파마Licensing deal
Oct 2809:38

Major동아에스티, 2거래일 연속 상승…3분기 영업이익 27.7% 증가, DA-1726 임상 주목
CBC뉴스Earnings
Oct 2808:09

동아에스티 목표가 6만원, 도입 신약 성장·엑스코프리 11월 출시-다올
PRESS9
Oct 2806:20

[IB토마토]동아에스티, ADC 성장 베팅…앱티스 자본잠식에 지원 부담
뉴스토마토
Oct 2719:29

[HIT알공] 동아에스티, 영업이익 증가...한미약품은 감소
히트뉴스Hanmi Pharm
Oct 2715:07

동아에스티, 3분기 영업익 214억원…전문의약품 성장에 수익성 개선
EBN
Oct 2715:07
Major동아에스티, 3분기 매출 2065억…전년比 4.1%↑
핀포인트뉴스Earnings
1 more on this story · 1 outlets
- 동아에스티, 3분기 매출 2065억…전년비 4.1% 증가데일리한국 · Oct 27 15:31
Oct 2715:01
동아에스티·에스티팜, 3분기 나란히 성장…매출·영업익 동반 증가
조선비즈ST Pharm
1 more on this story · 1 outlets
- 동아에스티·에스티팜, 3분기 나란히 성장…매출·영업익 동반 증가조선일보 · Oct 27 15:09
Oct 2713:18

MajorBreaking동아에스티, 3Q 영업익 213억원 … 전년比 27.7% 증가
뉴데일리경제Earnings
Oct 2713:13
동아에스티, 3분기 매출 2,065억 원… 2분기 연속 2,000억 돌파
디스커버리뉴스
2 more on this story · 2 outlets
- 동아에스티, 3분기 영업익 214억원…2분기 연속 매출 2,000억 돌파SR타임스 · Oct 27 16:10
- 동아에스티, 3분기 영업익 27.7%↑⋯매출 2분기 연속 2000억코메디닷컴 · Oct 27 18:21
Oct 2712:50

동아에스티, 3분기 영업익 214억⋯전년 동기 比 27.7% ↑
브릿지경제Earnings
Oct 2711:58
동아에스티, 3분기 영업이익 214억원…전년 대비 27.7% 증가
더트래커Earnings
3 more on this story · 3 outlets
- 동아에스티, 3분기 영업익 214억⋯전년 대비 27.7% 증가아이뉴스24 · Oct 27 14:29
- 동아에스티, 3분기 영업익 214억…전년比 27.7% 증가서울경제 · Oct 27 14:36
- 동아에스티, 3분기 매출 2065억원…영업이익 27.7% 증가아시아타임즈 · Oct 27 16:11
Oct 2711:51
Major동아에스티, 3Q 매출 4.1% 증가 2065억원…2분기 연속 2000억원 매출 돌파
더바이오Earnings
1 more on this story · 1 outlets
- 동아에스티, 3분기 매출 2065억원…2분기 연속 2000억원 돌파파이낸셜포스트 · Oct 27 15:08
Oct 2709:50

동아에스티 바르는 건선 치료제 가능성 입증
뉴스클레임
Oct 2709:39

[위클리오늘] 동아제약, 동아에스티(10.27)
위클리오늘Dong-A Socio Holdings
Oct 2709:18
동아에스티, '이코트로킨라' 외용제 가능성 확인…건선 제형 확장
메디파나뉴스
5 more on this story · 5 outlets
- 동아에스티 "건선 치료제 '이코트로킨라' 외용제 개발 가능성 확인"뉴스1 · Oct 27 09:35
- 동아에스티, 건선 치료제 '이코트로킨라' 외용제 개발 가능성 확인뉴스핌 · Oct 27 09:37
- 동아에스티, 건선 치료제 ‘이코트로킨라’ 외용제 개발 가능성 확인더바이오 · Oct 27 09:39
- 동아에스티, 경구용 건선 치료제 '이코트로킨라' 외용제 개발 가능성 확인메디팜스투데이 · Oct 27 09:49
- 동아에스티, 경구 건선약 '이코트로킨라' 외용제 전환 가능성 확인뉴데일리경제 · Oct 27 11:33
Oct 2618:25

웨어러블로 심박·심전도 실시간 확인…동아에스티·메쥬 체험존 운영
더퍼블릭Mezoo
Oct 2610:54

동아에스티, ‘세계 맥박의 날’ 웨어러블 모니터링 기기 ‘하이카디’ 체험존 운영
더바이오
Oct 2406:52

동아에스티 '슈가논' 10년, 복합제 성분 다변화ㆍ임상 근거 축적
의약뉴스
Oct 2115:45

동아에스티, 디지털 헬스케어 시장서 존재감 UP
이코노믹리뷰
Oct 2112:40

[위클리오늘] 산업일반 소식_동아에스티, 온코닉테라퓨틱스(10.21)
위클리오늘Onconic Therapeutics
Oct 2109:21

[MK 골든크로스 돌파종목 : 동아에스티(170900) & KR모터스(000040)]
매일경제KR Motors
Oct 2108:32
동아에스티, 솔티드와 AI 보행분석 솔루션 ‘뉴로게이트’ 국내 독점 판매
한국금융신문
1 more on this story · 1 outlets
- 동아에스티, 솔티드와 AI 보행분석 솔루션 ‘뉴로게이트’ 국내 독점 유통 계약 체결인더스트리뉴스 · Oct 21 09:31
Oct 2107:06

동아에스티 '이뮬도사' 유럽 허가범위 확대…소아 크론병 2세 이상
메디코파마
Oct 2019:12

‘오팔몬’ 영업망 시너지 노린다… 동아에스티, 근골격계 AI 진단 시장 진출
더퍼블릭

Articles per day 2 weeks

619

320

621

124

226

2527

328

129

1030

Company profile

CEO: 정재훈
Industry: Pharmaceuticals
Founded: 2013-03-04
Fiscal year-end: December
Head office: 서울 동대문구
Website: donga.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Dong-a ST dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩700	1.4%	–
FY2024	₩700	1.4%	–
FY2023	₩700	1.1%	53.1%

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

동아제약41.52%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Pharmaceuticals

All in industry

Company	Latest quarter op. profit	Articles 30d
Hanmi Pharm	₩131bn	656
Yuhan	₩66.9bn	492
Daewoong Pharma	₩68.1bn	376
GC Biopharma	₩1.7bn	330
DongKookPharmaceutical	₩26.1bn	256
Daewon Pharmaceutical	−₩9m	201
Kwangdong Pharmaceutical	₩2.8bn	187
JW Pharmaceutical	₩33.3bn	185

Compare Dong-a ST side by side with these companies

Dong-a ST DART filings

15:59

Clinical trial 투자판단관련주요경영사항 (제2형 당뇨병 치료 복합제 슈가엠파정 국내 품목허가 승인)
Clinical & patents
Oct 2713:15

Investor relations event 기업설명회(IR)개최(안내공시)
Other
Oct 2711:20

Preliminary earnings 영업(잠정)실적(공정공시)
Earnings & dividends
Oct 2215:59

Investor relations event 기업설명회(IR)개최(안내공시)
Other
Oct 2215:58

Other 결산실적공시예고(안내공시)
Other
Oct 2215:56

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports

Catalysts 2 weeks

Earnings11
Clinical & approvals6
Contracts & orders3

Mentioned alongside 2 weeks

Related themes

Obesity drugs1

Dong-a ST FAQ

Who is the CEO of Dong-a ST?: According to the DART company overview, Dong-a ST's representative director is 정재훈 (name as registered in Korean). The company was founded on 2013-03-04.
Where is Dong-a ST listed?: Dong-a ST trades on the Korea Exchange KOSPI market under the ticker 170900. Its fiscal year ends in December.
What were Dong-a ST's latest quarterly results?: In Q2 2026, Dong-a ST reported revenue of ₩225bn, up 15.8% year on year, and operating profit of ₩6.3bn. Figures come from reports filed on DART.
Does Dong-a ST pay a dividend?: Yes. For fiscal 2025, Dong-a ST paid a cash dividend of ₩700 per common share, a 1.4% yield as stated in its annual report. The prior year's dividend was ₩700.
Does Dong-a ST have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Turnaround (latest quarter swung to an operating profit from a loss a year earlier); Clinical trial filing (filing on clinical trial plans or results (90 days)). These are factual flags, not investment advice.
Which companies are in the same industry as Dong-a ST?: Under the Korean Standard Industrial Classification recorded on DART, Dong-a ST is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.